(Q32061029)

English

Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 July 2017

Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione (English)

1 reference

Europe PubMed Central

6 July 2017

1 reference

based on heuristic

inferred from title

author name string

F E Yakubu-Madus

1

1 reference

Europe PubMed Central

6 July 2017

T W Stephens

2

1 reference

Europe PubMed Central

6 July 2017

W T Johnson

3

1 reference

Europe PubMed Central

6 July 2017

publication date

1 June 2000

1 reference

Europe PubMed Central

6 July 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

6 July 2017

2

1 reference

Europe PubMed Central

6 July 2017

3

1 reference

Europe PubMed Central

6 July 2017

155-163

1 reference

Europe PubMed Central

6 July 2017

Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Mechanism of free fatty acid-induced insulin resistance in humans

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? mice

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Acute effects of troglitazone on in vivo insulin action in normal rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Insulin resistance in soleus muscle from obese Zucker rats. Involvement of several defective sites

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00075.X

21 January 2018

Identifiers

10.1046/J.1463-1326.2000.00075.X

1 reference

Europe PubMed Central

6 July 2017

1 reference

Europe PubMed Central

6 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q32061029&oldid=1541429021"